Indirubin

Indirubin is a natural bisindole compound that occurs in Indigo naturalis, a traditional Chinese medicine prepared from plants such as Indigofera tinctoria and Isatis tinctoria. It is one of the active constituents thought to contribute to the biological effects of Indigo naturalis, including antiproliferative and anti-inflammatory properties. Indirubin and its derivatives have been the subject of scientific study as potential kinase inhibitors.

Chemically, indirubin consists of two indole units connected to form a bisindole framework with adjacent carbonyl groups. This structure underpins its ability to interact with various protein kinases. Research has identified inhibitory activity against enzymes such as cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3), among others, which is linked to its effects on cell cycle progression and proliferation.

In vitro and preclinical studies have explored indirubin’s potential in cancer, inflammatory diseases, and glaucoma models, among others. Indirubin and several its derivatives have shown antiproliferative, anti-inflammatory, and anti-angiogenic activities in cell-based assays. Derivatives such as indirubin-3'-monoxime have been developed to enhance kinase inhibition and pharmacokinetic properties.

Clinical use of indirubin remains limited. Indigo naturalis has been employed in traditional practices for conditions including leukemia and psoriasis, but indirubin itself is not widely approved as a standard pharmaceutical in most jurisdictions. Its poor solubility and pharmacokinetic challenges have driven the development of synthetic derivatives and formulations aimed at improving bioavailability and selectivity, while maintaining a neutral assessment of benefits and risks.